NCT02384317View on ClinicalTrials.gov

Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 27, 2015

Primary Completion Date

September 13, 2015

Study Completion Date

June 1, 2018

Conditions
Immunoglobulin A Nephropathy
Interventions
DRUG

CCX168

CCX168 30 mg, twice daily (b.i.d.) orally for 84 days (12 weeks). The CCX168 dose was taken in the morning, optimally within one hour after breakfast, and in the evening, optimally within one hour after dinner.

Trial Locations (6)

Unknown

Palo Alto

San Francisco

Reno

Chapel Hill

Columbus

Stockholm

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY